This is a single-center, placebo-controlled, randomized, double-blind, dose-escalation study to evaluate safety, tolerability, and PK of a single oral (PO) administration of PCO371 in healthy adult males.

Caucasian and Japanese subjects will be randomized to receive either PCO371 or placebo.

Inclusion Criteria:

• Healthy male volunteers aged 18 to 45 years.
• Caucasian(BMI 18-30 mg/kg2) or first generation japanese(BMI 18-25kg/m2)
• Able and willing to abide by the protocol

Exclusion Criteria:

• Evidence of any medical condition that could affect renal, hepatic, or cardiopulmonary functions.